Lippman Evan 4

What Happened

• Evan Lippman, EVP, Business Development of Teva Pharmaceutical Industries Ltd. (TEVA), was granted 27,347 restricted share units (RSUs) on March 4, 2026. The RSUs were issued at $0.00 (no cash paid) and are recorded as a derivative award on the Form 4.

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (filed within the typical two-business-day window).
• Award size: 27,347 RSUs; grant price reported as $0.00 (no cash consideration).
• Vesting schedule: 6,836 RSUs vest on each of March 4, 2027, 2028 and 2029, and 6,839 RSUs vest on March 4, 2030.
• Shares owned after transaction: Not reported on the Form 4.
• Footnotes: Each RSU represents a contingent right to receive one ordinary share at settlement, or, at the committee's option, the cash value of one ordinary share. Ordinary shares may be represented by American Depositary Shares (ADS), each currently representing one ordinary share.

Context

• This is a restricted-share award (derivative grant), not an open-market purchase or sale. Grants are typically compensation-based and vest over time; they do not necessarily signal immediate buying or selling intent. The filing appears timely.